RFL
NYSE · Pharmaceuticals
Rafael Holdings Inc-Class B
$2.05
+0.03 (+1.49%)
Financial Highlights (FY 2026)
Revenue
1.65M
Net Income
-55,029,847
Gross Margin
85.4%
Profit Margin
-3,328.2%
Rev Growth
+30.8%
D/E Ratio
0.01
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 85.4% | 85.4% | 64.7% | 64.7% |
| Operating Margin | -3,179.8% | -2,861.8% | 39.4% | 41.4% |
| Profit Margin | -3,328.2% | -3,161.8% | 31.9% | 33.1% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 1.65M | 1.26M | 15.20M | 11.49M |
| Gross Profit | 1.41M | 1.08M | 9.83M | 7.43M |
| Operating Income | -52,533,303 | -36,152,295 | 5.98M | 4.75M |
| Net Income | -55,029,847 | -37,870,364 | 4.84M | 3.80M |
| Gross Margin | 85.4% | 85.4% | 64.7% | 64.7% |
| Operating Margin | -3,179.8% | -2,861.8% | 39.4% | 41.4% |
| Profit Margin | -3,328.2% | -3,161.8% | 31.9% | 33.1% |
| Rev Growth | +30.8% | +30.8% | +5.7% | +21.9% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 393.9K | 393.9K | 15.10M | 12.46M |
| Total Equity | 53.96M | 53.96M | 46.21M | 51.47M |
| D/E Ratio | 0.01 | 0.01 | 0.33 | 0.24 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -52,059,333 | -37,816,459 | 7.34M | 5.98M |
| Free Cash Flow | — | — | 4.44M | 4.05M |